Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2022-12-20 Director's Dealing
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice 2 pages 137.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities held by a director who has ceased to be a director, including shares and options. This is a report of personal share transactions or holdings by a company director. The document length is short (2182 characters) and contains specific information about director's interests in securities, which aligns with the definition of Director's Dealing filings. There is no indication that this is an announcement of a report or a general regulatory filing, but a specific insider transaction notice. Therefore, the correct classification is Director's Dealing (DIRS).
2022-12-20 English
Application for quotation of securities - NTI 6 pages 27.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX by Neurotech International Limited. It details the number and type of securities to be quoted, issue dates, and distribution schedules. It references a previous Appendix 3B announcement related to the securities issuance. The content is focused on the issuance and quotation of new shares, not on financial results, management changes, or other report types. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes. The document length is about 5,456 characters, and it contains substantive details about the securities issuance, not just a brief notice or a report publication announcement.
2022-12-20 English
Commencement of Phase II/III ASD Clinical Trial 2 pages 177.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 December 2022 from Neurotech International Limited. It announces the commencement of patient randomisation and the first patient treated in a Phase II/III clinical trial for Autism Spectrum Disorder (ASD). The content focuses on clinical trial progress, study design, endpoints, and regulatory approvals (HREC and TGA). There are no financial statements, earnings data, or management discussion of financial results. The document is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial commencement and design, not just a notice of report availability. The document fits best into the category of a general regulatory announcement about company progress and clinical trial updates, which aligns with Regulatory Filings (RNS).
2022-12-18 English
Chairman Address to 2022 Annual General Meeting 3 pages 115.8KB
AGM Information Classification · 95% confidence The document is titled 'Chairman Address to 2022 Annual General Meeting' and is dated 30 November 2022. It contains the Chairman's speech overviewing the company's financial year highlights, governance activities, strategic plans, and clinical trial progress. It also discusses board appointments and capital raising. The content is clearly a presentation or speech delivered at the Annual General Meeting (AGM) rather than a full annual report or financial statements. The document length is 8156 characters, which is consistent with a detailed AGM address. There is no detailed financial data or audit information, so it is not an Annual Report (10-K) or Audit Report (AR). The focus on the AGM event and the Chairman's address aligns with the AGM Information category.
2022-11-29 English
2022 Annual General Meeting Presentation 22 pages 2.5MB
AGM Information Classification · 95% confidence The document is titled '2022 Annual General Meeting' and contains a presentation by an Executive Director dated 30 November 2022. The content includes strategic focus, clinical trial updates, pipeline progress, and commercialisation examples, all typical of materials shared during an AGM. There is no indication of full financial statements or detailed financial performance data that would classify it as an Annual Report (10-K) or Interim Report (IR). The document is a presentation prepared for the AGM, including forward-looking statements and disclaimers typical of investor presentations at such meetings. Therefore, this document fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), supporting that it is a full presentation rather than a brief announcement or regulatory filing.
2022-11-29 English
Results of Meeting 3 pages 170.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 30 November 2022, titled 'Results of Annual General Meeting'. It details the outcomes of resolutions voted on at the Annual General Meeting (AGM) of Neurotech International Limited. The content includes proxy vote counts and poll results for various resolutions, which is typical for a declaration of voting results following an AGM. There is no indication that this document is the AGM presentation materials themselves, nor is it a full annual report or financial statement. The document is focused on the official results of shareholder votes at the AGM, matching the definition of 'Declaration of Voting Results & Voting Rights Announcements'. The document length is about 5237 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2022-11-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.